Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Anus Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × bintrafusp alfa protein, human × Clear all
NCT04708067 2026-03-05

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
2 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡